Genocea announced back in September that its interim results for its 140 patient Phase 1/2 generated T-cell responses, as well reductions in viral sheddings.
Vical has just started recruiting.
Did GSK's failed Phase 3 HerpeVac illicit a T-cell response?
It should be noted Bill Halford is not impressed with Genocea's results. Having said that, I don't think he's impressed with any programs except his own.
updated ballieu report - target range 25-55c, page-49
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.20 |
Change
-0.550(5.12%) |
Mkt cap ! $215.6M | |||
| Open | High | Low | Value | Volume |
| $10.73 | $10.73 | $10.15 | $109.7K | 10.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 490 | $10.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.20 | 911 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |